Preston S Klassen MD Appointed to the BOD of Regulus Therapeutics

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced Preston S. Klassen, M.D., President and Head of Research & Development, has been appointed to the Company’s Board of Directors.

“We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD,” said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus. “His expertise in nephrology, along with his previous leadership and board experience in the industry, will make him an invaluable member, and we look forward to his contributions to Regulus and our science.”

Preston S Klassen MD recently joined Regulus Therapeutics as President and Head of Research and Development. Dr. Klassen is a nephrologist by training who brings over 20 years of experience in pharmaceuticals, including positions in leadership, medical affairs, and research and development across multiple therapeutic areas. Most recently he served as the President and CEO of Metacrine. Prior to that, he was an Executive Vice President and Head of R&D at Arena Pharmaceuticals, CMO and President at SANIFIT, and Senior Vice President and Head of Global Development at Orexigen Therapeutics. Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology. Dr. Klassen earned his M.D. from the University of Nebraska Medical Center and completed both his residency in internal medicine and fellowship in nephrology as well as his Master’s in Health Sciences at Duke University Medical Center.

Other Executives In the News

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr. Val Kolesnitchenko brings extensive ophthalmology experience in clinical practice and industry to new therapeutics for the aging eye.
These strategic appointments signify a significant milestone for BRIJ Medical as they usher in a new era of post-surgical and trauma incision care with proven technologies that minimize wound complications and scarring.
Dr. Eckhard von Keutz has extensive experience in designing and conducting preclinical/toxicological studies, and toxicological risk assessment and management.
David Kroekel has more than 35 years of experience in medical device, combination product operations, and product development.
Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus. "Dr. Kousoulas...

By using this website you agree to accept Medical Device News Magazine Privacy Policy